Corcept Therapeutics (CORT) Enterprise Value (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Enterprise Value data on file, last reported at -$338.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 4.78% year-over-year to -$338.2 million; the trailing twelve-month figure through Mar 2026 stood at -$338.2 million (down 4.78% YoY), and the FY2025 full-year result was -$372.2 million, up 2.92% from the prior year.
• Enterprise Value improved to -$338.2 million in Q1 2026, from -$372.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$322.8 million in Q1 2025 to a low of -$473.2 million in Q2 2024.
• A 5-year average of -$384.7 million and a median of -$372.2 million in 2025 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value slumped 93.11% in 2022 and grew 27.67% in 2025, its largest moves.
• Tracing CORT's Enterprise Value over 5 years: stood at -$431.7 million in 2022, then grew by 14.7% to -$368.2 million in 2023, then declined by 4.1% to -$383.3 million in 2024, then gained by 2.92% to -$372.2 million in 2025, then grew by 9.13% to -$338.2 million in 2026.
• Business Quant data shows CORT's Enterprise Value at -$338.2 million in Q1 2026, -$372.2 million in Q4 2025, and -$421.7 million in Q3 2025.